| Market Cap | 55.68B | P/E | 67.53 | EPS this Y | -10.30% | Ern Qtrly Grth | 65.30% |
| Income | 200.73B | Forward P/E | 38.21 | EPS next Y | 36.10% | 50D Avg Chg | -8.00% |
| Sales | 1.6T | PEG | 57,105.80 | EPS past 5Y | 15.84% | 200D Avg Chg | -11.00% |
| Dividend | 99.00% | Price/Book | 0.04 | EPS next 5Y | 0.16% | 52W High Chg | -23.00% |
| Recommedations | 1.00 | Quick Ratio | 1.52 | Shares Outstanding | 1.92B | 52W Low Chg | 17.00% |
| Insider Own | 1.45% | ROA | 4.43% | Shares Float | 1.89B | Beta | 0.29 |
| Inst Own | 49.43% | ROE | 12.83% | Shares Shorted/Prior | -/- | Price | 29.04 |
| Gross Margin | 74.07% | Profit Margin | 12.53% | Avg. Volume | 8,196 | Target Price | 36.21 |
| Oper. Margin | 3.98% | Earnings Date | Jul 28 | Volume | 1,436 | Change | -4.28% |
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.